Skill Guide

FDA SaMD regulatory pathways (510(k), De Novo, PMA) and the Predetermined Change Control Plan framework

The FDA SaMD regulatory pathways (510(k), De Novo, PMA) are the three primary submission routes for classifying and obtaining clearance/approval for Software as a Medical Device, with the Predetermined Change Control Plan (PCCP) framework enabling iterative AI/ML updates post-market without a new submission for each change.

Mastery of these pathways directly determines a SaMD product's time-to-market, development cost, and long-term commercial viability, making it a non-negotiable core competency for regulatory, quality, and product leadership in digital health. This skill transforms regulatory strategy from a compliance bottleneck into a strategic competitive advantage for scalable AI/ML-driven medical software.

1 Careers

1 Categories

9.1 Avg Demand

15% Avg AI Risk

How to Learn FDA SaMD regulatory pathways (510(k), De Novo, PMA) and the Predetermined Change Control Plan framework

1. Master foundational definitions: Differentiate between SaMD, SiMD, and hardware-based medical devices. Understand the FDA's SaMD risk categorization framework (categorization I-IV) based on device function and healthcare situation/criticality. 2. Learn the core purpose and statutory basis of each pathway (510(k) 'substantial equivalence', De Novo 'novel, low-to-moderate risk', PMA 'high risk') and their corresponding FDA review divisions (CDRH). 3. Study the basic anatomy of a 510(k) submission: Predicate device comparison, performance testing requirements, and the 'Intended Use' statement.

1. Practice constructing a regulatory strategy memorandum for a hypothetical SaMD, justifying the chosen pathway (e.g., why a new AI-based diagnostic image analyzer should use the De Novo pathway over a 510(k) with a questionable predicate). 2. Deep-dive into the Quality System Regulation (QSR) and its intersection with SaMD development (ISO 13485), focusing on design controls and software validation (IEC 62304). 3. Avoid the common mistake of underestimating the 'Intended Use' statement's power to shift a device into a higher risk category or render a predicate device non-equivalent.

1. Master the PCCP framework as a strategic tool: Develop a PCCP for a continuously learning AI/ML SaMD, defining modification protocols, algorithm change protocols, and performance monitoring to lock in a regulatory pathway for future iterations. 2. Engage in complex, cross-functional regulatory strategy, aligning R&D, product, and commercial teams on a phased regulatory roadmap (e.g., launching via De Novo, then pursuing new indications via 510(k) supplements). 3. Lead pre-submission (Pre-Sub) meetings with the FDA, effectively negotiating data requirements and pathway selection for ambiguous, cutting-edge technologies like generative AI in clinical decision support.

Practice Projects

Beginner

Project

Regulatory Pathway Selection Analysis

Scenario

You are given a device brief: 'An AI-powered mobile app that analyzes photos of skin lesions to provide a malignancy risk score for initial patient screening.'

How to Execute

1. Use the FDA's SaMD categorization framework to determine the device's risk category (likely Category III). 2. Research existing FDA-cleared/approved AI-SaMDs for dermatology on the FDA's 510(k)/De Novo/PMA databases. 3. Draft a one-page analysis comparing the merits and requirements of pursuing a 510(k) (if a predicate exists), De Novo (for novel technology), or PMA (if risk is deemed high), with a final justified recommendation.

Intermediate

Case Study/Exercise

Pre-Submission Meeting Preparation

Scenario

Your company has developed a cloud-based SaMD that uses a deep learning algorithm to predict patient deterioration from vital sign data streams in a hospital setting. The algorithm's performance improves with new patient data.

How to Execute

1. Formulate a comprehensive list of questions for the FDA, focusing on: the recommended regulatory pathway, the appropriateness of using a PCCP for the learning algorithm, and specific clinical evidence requirements. 2. Prepare a 10-slide briefing document that outlines your device, its technology, intended use, proposed regulatory strategy, and specific questions. 3. Conduct a mock meeting with a colleague playing the FDA reviewer, practicing clear, concise, and data-driven responses to challenging questions.

Advanced

Case Study/Exercise

PCCP Strategy & Documentation

Scenario

You are leading the regulatory strategy for a SaMD that uses a locked (static) algorithm for primary diagnosis (Category IV) but has a separate module that provides risk stratification using a continuously adaptive algorithm (Category II).

How to Execute

1. Draft the high-level sections of a PCCP for the adaptive module, explicitly defining the 'Software Change Protocol' for the locked algorithm vs. the 'PCCP Modification Protocol' for the adaptive one. 2. Develop the 'Algorithm Change Protocol' for the adaptive module, specifying the data collection, re-training triggers, and performance validation boundaries that will be pre-specified for the FDA. 3. Author a regulatory strategy document that presents this bifurcated approach to the FDA, arguing for the PCCP's adequacy to manage the adaptive module's risk while addressing the locked algorithm's PMA-level requirements through a separate, traditional submission.

Tools & Frameworks

Regulatory & Guidance Documents

FDA Guidance: 'Software as a Medical Device (SaMD): Clinical Evaluation'FDA Guidance: 'Predetermined Change Control Plans for ML-Enabled Device Software Functions'FDA Guidance: 'Content of Premarket Submissions for Device Software Functions'FDA's SaMD Risk Categorization Framework

These are the primary references for defining intended use, categorizing risk, structuring submissions, and building a PCCP. They are non-negotiable reading for any regulatory strategy.

Quality & Development Standards

IEC 62304: Medical device software - Software life cycle processesISO 14971: Application of risk management to medical devicesISO 13485: Medical devices - Quality management systems

These international standards form the backbone of the Quality Management System (QMS) required for SaMD development. IEC 62304 dictates software documentation rigor, ISO 14971 is used for hazard analysis, and ISO 13485 is the QMS framework.

Tools & Databases

FDA 510(k) Premarket Notification DatabaseFDA De Novo Classification DatabaseFDA Premarket Approval (PMA) DatabaseClinicalTrials.gov

Essential for research and competitive intelligence. The databases are used to identify predicates, understand precedent for novel devices, and study approved clinical trial designs for similar SaMDs.

Interview Questions

Answer Strategy

The interviewer is testing your understanding of pathway eligibility criteria and strategic risk assessment. Use a framework: 1) Assess 'Substantial Equivalence' by searching for a legally marketed predicate with the same intended use and technological characteristics. 2) If no predicate exists, De Novo is the path. 3) Even if a loose predicate exists, argue for De Novo if the technology is truly novel (e.g., a fundamentally different algorithmic approach) to establish a new regulatory category and avoid predicate limitations. Key evidence tipping the scale: gaps in predicate intended use, superior performance claims requiring new clinical evidence, or the use of a PCCP for continuous learning.

Answer Strategy

This tests resilience, problem-solving, and knowledge of regulatory pathways. Demonstrate a structured response: 1) Acknowledge the feedback and request a teleconference to understand the specific deficiencies (is it intended use, technology, or performance?). 2) Immediately pivot to a dual-track strategy: a) conduct a more exhaustive search for a better predicate (including cleared PMA panel supplements), and b) begin building the case for a De Novo submission by gathering the additional data (clinical performance, usability) that would support it. 3) Present this revised strategy to leadership with clear resource implications.